# A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee

> **NCT01554579** · PHASE2 · COMPLETED · sponsor: **Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 171 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Sugar Pill

## Key facts

- **NCT ID:** NCT01554579
- **Lead sponsor:** Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-29
- **Primary completion:** 2013-11-11
- **Final completion:** 2013-11-21
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554579, "A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01554579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*